Biogen present new TECFIDERA (dimethyl fumarate) research at the 68th annual meeting of the American Academy of Neurology (AAN) in Vancouver, Canada. The data presented supports the value of dimethyl fumarate in the treatment of patients with ... Hospital Pharmacy Europe, 1 month ago
TECFIDERA® Data Confirm Strong and Sustained Efficacy in Newly Diagnosed MS Patients and Real-World Effectiveness - Bloomberg, 1 month ago
Tecfidera demonstrates sustained efficacy in RRMS studies - European Pharmaceutical Review, 1 month ago
More from: CNBC, Minyanville...and 24 other sources
1 images for "Tecfidera Treated Patients"
Medicationdiscountcard.com Provides Prescription Coupons to Patients With Multiple Sclerosis: In Tandem With New Treatments
Presription Savings Card Atlantic City, NJ (PRWEB) April 19, 2016 Over 400,000 Americans live with Multiple Sclerosis (MS) every day. There are an estimated 10,000 new cases diagnosed each year. New therapies that slow the progression of ...PRWeb, 1 month ago FDA approves new Biogen multiple sclerosis drug Boston Globe, 4 days ago
EMD Serono to Present Data Assessing Comparative Effectiveness of Rebif® (interferon beta-1a) vs. TECFIDERA® (dimethyl fumurate) at AAN Annual Meeting
_ A real-world assessment of relapse rates in patients with MS newly initiating self-injectable treatment with Rebif versus an oral disease-modifying therapy, as well as the clinical effect of Rebif on 'no evident disease activity' (NEDA) and MRI ...Sys-Con Media, 1 month ago
Dermatologists and their patients have benefited immensely from the expanded armamentarium of treatment options for plaque psoriasis. Nevertheless, they may still be challenged by patients with coexisting systemic diseases or other psoriasis ...Dermatology Times, 1 month ago
Strong Product Portfolio Drove Biogen's 1Q16 Profit Margins ( Continued from Prior Part ) Tecfidera performance By the end of 1Q16, Biogen's (BIIB) leading multiple sclerosis (or MS) drug, Tecfidera, had treated about 190,000 multiple ...Yahoo! Finance UK and Ireland, 1 month ago
More from: , Yahoo! Finance...and 1 other sources
New Study By Spherix Global Insights Indicates High Therapy Switching Rates For Multiple Sclerosis Patients In The US And EU, Benefitting Biogen's...
New Study By Spherix Global Insights Indicates High Therapy Switching Rates For Multiple Sclerosis Patients In The US And EU, Benefitting Biogen's Tecfidera, Novartis' Gilenya And Sanofi's Aubagio By a News Reporter-Staff News Editor at Pharma ...Equities.com, 1 month ago
There seems to have been more Tecfidera progressive multifocal leukoencephalopathy (PML) cases reported in the past year or so. And it seems that lymphonpenia possibly induced by Tecfidera might have a role to play in those additional PML cases. ...DrugInjuryLaw.com, 2 weeks ago A Tecfidera Label Change Modifying Warnings About Progressive Multifocal Leukoencephalopathy (PML) Was Done In February 2016 With Little Notice Drug Injury Watch, 2 weeks ago
25/05/2016 2:29pm UK Regulatory (RNS & others) TIDMBIOG LONDON STOCK EXCHANGE ANNOUNCEMENT The Biotech Growth Trust PLC Audited Results for the Year Ended 31 March 2016 The Company's annual ...ADVFN UK, 6 days ago THE BIOTECH GROWTH TRUST PLC - Final Results Ariva.de, 6 days ago BIOTECH GROWTH : Final Results 4 Traders, 6 days ago
Fight! Fight! Fight! In this week's episode of Industry Focus: Healthcare , Kristine Harjes and Todd Campbell pit four of the pharmaceutical industry's biggest drug companies against each other to weigh out today's best buys for healthcare ...Motley Fool, 1 week ago
Introduction It's gotten to where I'm both thankful for the P/E of 7X or below in Gilead (NASDAQ: GILD ), but where I also want to say, from the disco era : Enough is enough is enough is enough is enough is enough I've had it... we've had ...Seeking Alpha, 1 week ago Better Buy: Gilead Sciences vs. Biogen Motley Fool, 3 weeks ago Better Buy Gilead Sciences vs. Biogen FOXBusiness.com, 3 weeks ago
on your WebpageAdd Widget >Get your members hooked!